Outstanding Questions to Understand and Target Splicing Factor-Mutant Blood Cancers.
Maxim I Maron, Omar Abdel-Wahab
https://pubmed.ncbi.nlm.nih.gov/42013378/Actively Recruiting
Led by Chordia Therapeutics, Inc. · Updated on 2026-04-13
225
Participants Needed
8
Research Sites
35 weeks
Total Duration
Researchers are evaluating CTX-712 in patients with relapsed or refractory acute myeloid leukemia AML and higher risk myelodysplastic syndromes HR-MDS, including MDSMPN such as CMML. This phase 12 multicenter, open-label study aims to assess the safety, tolerability, and how the drug behaves in the body, as well as its effects on RNA splicing. The study includes dose escalation and expansion to find the best dose and further evaluate therapeutic activity in these conditions. The study begins with phase 1 dose escalation using a standard 3 3 design, where patients receive increasing doses of CTX-712 once or twice weekly in 28-day cycles to identify the recommended phase 2 dose RP2D. After establishing the RP2D, expansion cohorts in AML and HR-MDS will receive CTX-712 at this dose. Additional cohorts may be added, including drug-drug interaction studies. Phase 2 will then evaluate the treatments activity and safety using the confirmed RP2D. Participants will be monitored closely through laboratory tests to assess organ function and blood counts. Safety is tracked by recording adverse events from consent through 28 days after the last dose. Pharmacokinetic and pharmacodynamic evaluations occur during treatment cycles, including blood sampling to study the drugs behavior and effects. The main outcomes measured include safety, maximum tolerated dose, complete remission rate, and other response and survival rates. Follow-up may continue up to 36 months to track long-term effects and transitions to stem cell transplantation.
CONDITIONS
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
L
Laurie F Graham, RN, MSN
H
Haris Durutlic
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Chordia Therapeutics, Inc.
Lead Sponsor
Theradex
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | CTX-712 Oral Treatment | Standard Care or Approved Therapies |
|---|---|---|
| What it is | An oral experimental drug (CTX-712) under investigation for relapsed/refractory AML and higher-risk MDS in a dose escalation and expansion single-arm trial. | Established current-care options such as hypomethylating agents (azacitidine, decitabine), venetoclax-based regimens, or best supportive care for eligible patients with relapsed/refractory AML or higher-risk MDS. |
| Role in the trial | CTX-712 is the only investigational treatment assigned in sequential dose cohorts to evaluate safety, tolerability, and efficacy. | Not a trial arm; standard treatments are presented for context and were not compared directly in this study. |
| Primary use | Investigated for potential anti-tumor activity and response induction in relapsed/refractory AML and HR-MDS. | Used as approved first- or later-line therapies to induce remission, prolong survival, or provide supportive care in AML/MDS after prior therapy. |
| How it is given or performed | Oral 20 mg tablet once or twice weekly depending on assigned dose cohort, with 28-day cycles. | Standard therapies include intravenous or subcutaneous regimens (e.g., azacitidine, decitabine), oral agents (venetoclax), or supportive care measures. |
| Evidence status | No published outcome results for CTX-712 yet; trial is ongoing and efficacy is under investigation. | Approved therapies are supported by published clinical trial data for efficacy in relapsed/refractory AML and HR-MDS, but outcomes vary based on prior therapy and patient characteristics. |
| Important limitations | Being a single-arm, cohort-based trial, CTX-712 has no direct comparator; dose escalation may limit generalizability and toxicity profile is not yet established. | Standard regimens have variable efficacy in relapsed/refractory AML/MDS and are limited by prior resistance, patient fitness, and adverse event profiles. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Repeated 28-day cycles until disease progression or discontinuation
Participants take CTX-712 tablets once or twice weekly depending on their dose level during each 28-day cycle.
Weekly visits for each treatment cycle
Duration - 28 days after last dose of CTX-712
Participants are monitored for safety and treatment outcomes after finishing the last dose of CTX-712.
Approximately 1 follow-up visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Maxim I Maron, Omar Abdel-Wahab
https://pubmed.ncbi.nlm.nih.gov/42013378/Hisayuki Yokoyama, Noriko Fukuhara, Koji Ando...
https://pubmed.ncbi.nlm.nih.gov/41056522/Chordia Therapeutics, Inc.
Lead Sponsor
Theradex
Collaborating Sponsor